RenovoRx Inc (RNXT)

[budfoxfun]

.72 thin on the ask here $RNXT Research Supports RenovoRx’s Lead Oncology Product Candidate, RenovoGem™, and its Novel Therapy Platform, TAMP™, for the Treatment of Locally Advanced Pancreatic Cancer

LOS ALTOS, Calif., December 19, 2023--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah. The abstract will highlight the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC), a difficult-to-access, solid tumor cancer.

"We are pleased to present research supporting our TAMP therapy platform at the upcoming SIR 2024 conference, the largest professional gathering of interventional radiologists in North America," said Shaun Bagai, CEO of RenovoRx. "This research adds to the continued progress of our pivotal Phase III TIGeR-PaC study in LAPC. We remain steadfast in our commitment to deliver transformative therapies to potentially extend and improve the quality of life of cancer patients."